



## Acetobacter indonesiensis Pneumonia after Lung Transplant

Fadi Bittar, Martine Reynaud-Gaubert, Pascal Thomas, Stéphanie Boniface,  
Didier Raoult, Jean-Marc Rolain

### ► To cite this version:

Fadi Bittar, Martine Reynaud-Gaubert, Pascal Thomas, Stéphanie Boniface, Didier Raoult, et al..  
Acetobacter indonesiensis Pneumonia after Lung Transplant. Emerging Infectious Diseases, 2008, 14  
(6), pp.997 - 998. 10.3201/eid1406.071236 . hal-01478697

**HAL Id: hal-01478697**

**<https://amu.hal.science/hal-01478697>**

Submitted on 12 Oct 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

8. Wade AJ, Walker T, Athan E, Hughes AJ. Spontaneous splenic rupture: a rare complication of Q fever in Australia. *Med J Aust.* 2006;184:364.
9. Barrio J, de Diego A, Ripoll C, Perez-Calle JL, Núñez O, Salcedo M, et al. Mediterranean spotted fever in liver transplantation: a case report. *Transplant Proc.* 2002;34:1255–6.
10. Rallis TM, Kriesel JD, Dumler JS, Waggoner LE, Wright ED, Spruance SL. Rocky Mountain spotted fever following cardiac transplantation. *West J Med.* 1993;158:625–8.

Address for correspondence: Marc Lecuit, Service des Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75015 Paris, France; email: mlecuit@pasteur.fr

## *Acetobacter indonesiensis* Pneumonia after Lung Transplant


**To the Editor:** Unusual and multiresistant bacterial infections are increasingly reported in cystic fibrosis (CF) patients (*1*). On January 25, 2007, a 31-year-old man with CF (mutation  $\Delta F$  508 and I 507) was admitted to our institution in Marseille, France, for lung transplantation. His immunosuppressive regimen included IV cyclosporin A (for the first 6 days with conversion to oral tacrolimus thereafter), azathioprine, and corticosteroids. Induction therapy that used antithymocyte globulin was administered for the first 3 days (Thymoglobuline, Genzyme Corporation, Naarden, the Netherlands). Since 2003, the patient was chronically colonized by methicillin-resistant *Staphylococcus aureus* (MRSA), *Pseudomonas aeruginosa* (susceptible only to colistin sulfomethate), and *Candida albicans*. Pre-emptive treatment with antimicrobial

agents including colistin sulfomethate, tobramycin sulfate, ceftazidime, and linezolid was administered, starting on posttransplant day 1; prophylactic caspofungin, followed by inhaled amphotericin B, was given for the first month. Six and 9 days, respectively, after surgery, sputa from the patient showed *P. aeruginosa* and MRSA.

On postoperative day 11, the patient's clinical condition worsened. Leukocytes increased to  $13.84 \times 10^9/L$ . In addition to *P. aeruginosa* ( $10^4$  CFU/mL) and MRSA ( $10^3$  CFU/mL), culture of later sputum samples yielded the growth of  $10^4$  CFU/mL of gram-negative, catalase-positive, and oxidase-negative bacillus (isolate 7120034) on CEPACIA agar (AES, Combourg, France) after 72 hours of incubation at 30°C. API 20NE, API

20E, and VITEK 2 Auto system (bioMérieux, Marcy l'Etoile, France) did not identify the bacillus. This bacterium was multiresistant to antimicrobial agents, including colistin, and was susceptible only to imipenem, rifampin, and aminoglycosides. The final identification of this isolate as *Acetobacter indonesiensis* was achieved after partial sequencing of 16S rRNA gene, as previously described (*2*) (GenBank accession no. AJ199841, 99% similarity). The sequence of our isolate has been deposited in GenBank under the accession no. EF681860. The phylogenetic position of isolate 7120034 among other gram-negative bacteria is shown in the Figure.

Tobramycin was stopped at day 11, colistin and ceftazidime were stopped at postoperative day 14, lin-



ezolid was maintained for 10 additional days, and gentamicin (for 13 days) was added to the patient's drug therapy on February 10. Despite this treatment, *A. indonesiensis* was cultured from sputa obtained on February 16 ( $10^4$  CFU/mL) and February 20 ( $10^2$  CFU/mL), respectively. Six days later, leukocytes decreased to  $8.62 \times 10^9/L$ , and the patient's condition improved. He was discharged at the beginning of March. During 7 months of follow-up, the *A. indonesiensis* strain was not found again.

Acetic acid bacteria are gram-negative bacilli classified into the genera *Acetobacter*, *Gluconobacter*, *Gluconacetobacter*, *Acidomonas*, and the recently described genus *Asaia*; these bacteria belong to the  $\alpha$  subgroup of *Proteobacteria* (3). Isolates of this family are recognized as food-associated bacteria and are able to grow at acidic pH (4). Three species have been reported as emerging pathogens in humans: *Asaia bogorensis* (in a case of peritonitis in a patient with a peritoneal dialysis catheter [5]); *Granulibacter bethesdensis* (in 3 cases of lymphadenitis associated with chronic granulomatous disease [6]); and *Acetobacter cibinongensis* (a recent case of bacteremia in a patient receiving chronic hemodialysis for end-stage renal failure [7]).

*A. indonesiensis* has been isolated from fruits and flowers in Indonesia (8); only 3 reports on it have been published (3,8,9). In our patient, we believe that this multidrug-resistant bacterium was the primary cause of the infection because the patient was eventually cured after an adapted antimicrobial drug therapy. Because this bacterium grows easily at acidic pH (4), a classic condition in the CF airway surface liquid, acidity might contribute to bacterial adhesion and colonization (10). Because acetic acid bacteria have never been isolated from human flora, the source of the contamination for our patient remains unknown.

We also report the antimicrobial drug susceptibility of this bacterium. It was multiresistant, especially to colistin. Antimicrobial drug susceptibility results were obtained by using Vitek 2 Auto system because of the absence of growth on Mueller-Hinton agar. This pattern was also the case for *G. bethesdensis* (6). The antimicrobial susceptibility of *A. cibinongensis* could not be validated because of the lack of interassay reproducibility (7). Initial antimicrobial drug therapy for this patient with amoxicillin, pristinamycin, and cefazolin did not cure the patient; he was eventually cured after the therapy was switched to tobramycin (7).

Our findings reemphasize the emergence of new colistin-resistant pathogens in CF patients, as recently reported for *Inquilinus limosus* (1). The increased clinical use of nebulized colistin for *P. aeruginosa* infection in CF patients may select specific colistin-resistant bacteria in such populations. In summary, this report of a respiratory tract infection caused by *A. indonesiensis* after lung transplantation in a French CF patient supports that this multidrug-resistant bacterium may be an emerging opportunistic pathogen in immunocompromised patients, including CF patients with a lung transplant.

**Fadi Bittar,\*  
Martine Reynaud-Gaubert,†  
Pascal Thomas,†  
Stéphanie Boniface,†  
Didier Raoult,\*  
and Jean-Marc Rolain\***

\*Unité de Research sur les Maladies Infectieuses et Tropicales Emergentes, Marseille, France; and †Hôpital Sainte Marguerite, Marseille

## References

1. Coenye T, Goris J, Spilker T, Vandamme P, Lipuma JJ. Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of *Inquilinus limosus* gen. nov., sp. nov. *J Clin Microbiol*. 2002;40:2062–9.

2. Drancourt M, Bollet C, Raoult D. *Stenotrophomonas africana* sp. nov., an opportunistic human pathogen in Africa. *Int J Syst Bacteriol*. 1997;47:160–3.
3. Cleenwerck I, Vandemeulebroecke K, Janssens D, Swings J. Re-examination of the genus *Acetobacter*, with descriptions of *Acetobacter cerevisiae* sp. nov. and *Acetobacter malorum* sp. nov. *Int J Syst Evol Microbiol*. 2002;52:1551–8.
4. Yamada Y, Hosono R, Lisdiyanti P, Widyastuti Y, Saono S, Uchimura T, et al. Identification of acetic acid bacteria isolated from Indonesian sources, especially of isolates classified in the genus *Gluconobacter*. *J Gen Appl Microbiol*. 1999;45:23–8.
5. Snyder RW, Ruhe J, Kobrin S, Wasserstein A, Doline C, Nachamkin I, et al. *Asaia bogorensis* peritonitis identified by 16S ribosomal RNA sequence analysis in a patient receiving peritoneal dialysis. *Am J Kidney Dis*. 2004;44:e15–7.
6. Greenberg DE, Ding L, Zelazny AM, Stock F, Wong A, Anderson VL, et al. A novel bacterium associated with lymphadenitis in a patient with chronic granulomatous disease. *PLoS Pathog*. 2006;2:e28.
7. Gouby A, Teyssier C, Vecina F, Marchandin H, Granolleras C, Zorogniotti I, et al. *Acetobacter cibinongensis* bacteremia in human. *Emerg Infect Dis*. 2007;13:784–5.
8. Lisdiyanti P, Kawasaki H, Seki T, Yamada Y, Uchimura T, Komagata K. Systematic study of the genus *Acetobacter* with descriptions of *Acetobacter indonesiensis* sp. nov., *Acetobacter tropicalis* sp. nov., *Acetobacter orleanensis* (Henneberg 1906) comb. nov., *Acetobacter lovaniensis* (Frateur 1950) comb. nov., and *Acetobacter estunensis* (Carr 1958) comb. nov. *J Gen Appl Microbiol*. 2000;46:147–65.
9. Lisdiyanti P, Kawasaki H, Seki T, Yamada Y, Uchimura T, Komagata K. Identification of *Acetobacter* strains isolated from Indonesian sources, and proposals of *Acetobacter syzygii* sp. nov., *Acetobacter cibinongensis* sp. nov., and *Acetobacter orientalis* sp. nov. *J Gen Appl Microbiol*. 2001;47:119–31.
10. Poschet J, Perkett E, Deretic V. Hyperacidification in cystic fibrosis: links with lung disease and new prospects for treatment. *Trends Mol Med*. 2002;8:512–9.

Address for correspondence: Jean-Marc Rolain, URMITE, CNRS-IRD UMR 6236, Faculté de Médecine et de Pharmacie, 27 Blvd Jean Moulin, 13385 Marseille, CEDEX 5, France; email: jm.rolain@medecine.univ-mrs.fr

All material published in *Emerging Infectious Diseases* is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.